Contact this trialFirst, we need to learn more about you.
Monoclonal Antibodies
Aducanumab for Alzheimer's Disease
Recruiting1 awardPhase 3
Belmont, Massachusetts
This trial is testing whether a drug called aducanumab can slow down cognitive and functional decline in people with early Alzheimer's disease, as measured by the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) score.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.